Scottish Medicines Consortium approves two AstraZeneca treatments for use within NHS Scotland

Scottish Medicines Consortium approves two AstraZeneca treatments

Scottish Medicines Consortium approves two AstraZeneca treatments for use within NHS Scotland.

IMFINZI▼ (durvalumab) is the first immunotherapy to be made available to patients with stage 3 unresectable non-small cell lung cancer (NSCLC) – a stage of lung cancer where the intention of treatment is cure.

Durvalumab has been accepted as monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 [programmed cell death ligand 1] on ≥1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy. AstraZeneca estimates that 75 patients could be eligible for treatment with durvalumab in the first year of it being available within NHS Scotland.

In Scotland, between 2016-2017, 1,967 people were diagnosed with stage 3 lung cancer. Approximately 80-85% of lung cancer cases are NSCLC. Stage 3 lung cancer is when the cancer has spread within the lungs and possibly lymph nodes, but has not yet reached other parts of the body. There may still be a chance of cure for stage 3 NSCLC, whereas if the patient progresses to stage 4 disease (also known as metastatic), treatment goals are limited to prolonging life and providing palliative care.

AstraZeneca estimates that 75 patients will be eligible for treatment with durvalumab in the first year of it being available within NHS Scotland.

FASENRATM▼ (benralizumab) has been made available as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta-agonists.

It has been accepted for restricted use at specific sites that can prescribe biologics within NHS Scotland. Use of benralizumab is restricted to patients with blood eosinophils of 150 cells or more per microlitre, and either:

  • 4 or more prior asthma exacerbations that needed systemic corticosteroids in the previous 12 months or
  • treatment with continuous oral corticosteroids over the previous 6 months.

AstraZeneca estimates that approximately 5,500 people in Scotland could be eligible for benralizumab.

AstraZeneca recently presented new data on durvalumab and benralizumab.